Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


pD40-His/V5-c-Myc Citations (8)

Originally described in: A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.
Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR, Sears R Nat Cell Biol. 2004 Apr;6(4):308-18. Epub 2004 Mar 14.
PubMed Journal

Articles Citing pD40-His/V5-c-Myc

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Wirth M, Stojanovic N, Christian J, Paul MC, Stauber RH, Schmid RM, Hacker G, Kramer OH, Saur D, Schneider G. Nucleic Acids Res. 2014;42(16):10433-47. doi: 10.1093/nar/gku763. Epub 2014 Aug 21. PubMed
EYA1's Conformation Specificity in Dephosphorylating Phosphothreonine in Myc and Its Activity on Myc Stabilization in Breast Cancer. Li J, Rodriguez Y, Cheng C, Zeng L, Wong EY, Xu CY, Zhou MM, Xu PX. Mol Cell Biol. 2016 Dec 19;37(1). pii: e00499-16. Print 2017 Jan 1. PubMed
Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TTT, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD. Clin Cancer Res. 2018 Nov 1;24(21):5392-5406. doi: 10.1158/1078-0432.CCR-18-1040. Epub 2018 Jul 23. PubMed
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. Nowak DG, Katsenelson KC, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MM, Casanova-Salas I, Jibilian MC, Buckholtz CL, Ambrico AJ, Pan CH, Wilkinson JE, Newton AC, Trotman LC. J Cell Biol. 2019 Jun 3;218(6):1943-1957. doi: 10.1083/jcb.201902048. Epub 2019 May 15. PubMed
Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease. Zhang D, Damoiseaux R, Babayan L, Rivera-Meza EK, Yang Y, Bergsneider M, Wang MB, Yong WH, Kelly K, Heaney AP. J Clin Endocrinol Metab. 2021 Jan 1;106(1):e232-e246. doi: 10.1210/clinem/dgaa699. PubMed
Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nguyen TTT, Shang E, Shu C, Kim S, Mela A, Humala N, Mahajan A, Yang HW, Akman HO, Quinzii CM, Zhang G, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. Nat Commun. 2021 Sep 1;12(1):5203. doi: 10.1038/s41467-021-25501-x. PubMed
Ubiquitylation of unphosphorylated c-myc by novel E3 ligase SCF(Fbxl8). Bajpai S, Jin HR, Mucha B, Diehl JA. Cancer Biol Ther. 2022 Dec 31;23(1):348-357. doi: 10.1080/15384047.2022.2061279. PubMed
The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC. Lee JS, Lero MW, Mercado-Matos J, Zhu S, Jo M, Tocheny CE, Morgan JS, Shaw LM. Cell Rep. 2022 Dec 6;41(10):111759. doi: 10.1016/j.celrep.2022.111759. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.